Equishield Ibh

Equishield Ibh

Equishield Ibh Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions


Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones, including ofloxacin. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an allergic reaction to ofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:


Gram-positive bacteria:Gram-negative bacteria:
Staphylococcus aureusEnterobacter cloacae
Staphylococcus epidermidisHaemophilus influenzae
Streptococcus pneumoniaeProteus mirabilis
Pseudomonas aeruginosa


*Efficacy for this organism was studied in fewer than 10 infections

Gram-positive bacteria:Gram-negative bacteria:Anaerobic species:
Staphylococcus aureusPseudomonas aeruginosaPropionibacterium acnes
Staphylococcus epidermidisSerratia marcescens*
Streptococcus pneumoniae


There is currently no drug history available for this drug.

Other Information

Ofloxacin Ophthalmic Solution USP, 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use.

Chemical Name: (±)-9-Fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de]-1,4 benzoxazine-6-carboxylic acid.

Contains: Active: ofloxacin 0.3% (3 mg/mL);

Inactives: sodium chloride and water for injection. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH.

Preservative: benzalkonium chloride (0.005%);

Ofloxacin Ophthalmic Solution USP, 0.3% is unbuffered and formulated with a pH of 6.4 (range - 6.0 to 6.8). It has an osmolality of 300 mOsm/kg. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure.

Basic Ring Structure

Equishield Ibh Manufacturers

  • Kinetic Technologies
    Equishield Ibh (Chlorhexidine Gluconate, Ketoconazole, Pramoxine Hydrochloride, Citronella, Hydrocortisone) Patch [Kinetic Technologies]
  • Kinetic Technologies
    Equishield Ibh (Chlorhexidine Gluconate, Ketoconazole, Pramoxine Hydrochloride, Citronella, Hydrocortisone) Spray [Kinetic Technologies]

Login To Your Free Account